Opticom International Research is pleased to invite people with haemophilia and parents to children with haemophilia to a focus group we are planning to conduct on behalf of a pharmaceutical company involved in providing treatment for haemophilia. Our client is interested in developing a support tool for people with haemophilia and we would like to invite you to discuss your needs and ideas in this respect.• Would you like to take part in a discussion and give your opinions on what kind of support is needed for people with haemophilia and how a tool should be developed?
• Are you available for participating in a group discussion that will last for approximately 2 hours during a weekday evening between the 17th and 28th of November and will be conducted in London?

About the focus group
Opticom International Research, an independent, global consultancy firm specializing in market analysis, will organize and lead the group discussions which will be objective and will not focus on your disease history or private matters. You will be offered something to eat and drink during the session. A compensation of 50 Euro will be paid to all participants

Interested?
If you are interested in taking part in a group discussion that may contribute to the development of a new support tool for people with haemophilia, please click here to register your interest. Opticom will get back to you with an invitation and more information as soon as possible.

Download PDF
Opticom International Research a le plaisir d’inviter des personnes atteintes d’hémophilie et des parents d’enfants atteints d’hémophilie à un groupe de discussion que nous prévoyons d’organiser pour le compte d’une société pharmaceutique qui dispense des traitements pour l’hémophilie. Notre client est intéressé à développer un outil de support pour les personnes atteintes d’hémophilie et nous aimerions vous inviter à venir discuter de vos besoins et idées à cet égard.• Aimeriez-vous participer à une discussion et donner vos avis sur le type de support dont les personnes atteintes d’hémophilie auraient besoin et de quelle manière un outil devrait être développé ?
• Êtes-vous disponible pour participer à un groupe de discussion qui durera environ 2 heures au cours d’une soirée en semaine entre le 17 et le 28 Novembre et qui se tiendra à Paris?

À propos du groupe de discussion
Opticom International Research, un cabinet conseil indépendant international, spécialisé dans l’analyse de marché, va organiser et diriger les discussions de groupe qui seront objectives et ne se concentreront pas sur l’histoire de votre maladie ou des affaires privées. Il vous sera proposé quelque chose à manger et à boire au cours de la session. Une compensation de 50 euros sera versée à tous les participants.

Intéressé?
Si vous êtes intéressé à participer à une discussion de groupe qui peut contribuer au développement d’un nouvel outil de support pour les personnes atteintes d’hémophilie, vous pouvez indiquer votre intérêt ici. Opticom vous fera parvenir une invitation et de plus amples informations dès que possible.

Download PDF

Collaboration is the key to a more holistic view and good health economics and the pharmaceutical industry should be a key player in this. At the same time, it may be high time for the pharmaceutical industry to revise not only its own strategies, but also its self image: To dare to stand for and communicate what the industry actually does and can do in the future. These are some of the results of this year’s industry study conducted by Opticom International Research in collaboration with the Pharma Industry and LIF.

Opticom International Research has since 2010 every year conducted a study in the Swedish pharmaceutical industry in collaboration with Pharma Industry, where people working in the pharmaceutical industry will offer their opinions and predictions for the industry. Since 2012, LIF (the trade association for the research-based pharmaceutical industry in Sweden) has also participated in conducting the study. The aim of the study is to identify the industry’s perception of itself and the perception of its role within the Swedish health care system in order to identify both opportunities and threats for the future.

Click here to read the full article about this survey on the pharmaceutical industry (in Swedish).

Download PDF

The unique Almedalen week is quickly approaching and on Wednesday the 2nd of July, Opticom invites to an After work event starting at 5 pm.

This year, we are organising the event together with Magnusson, the Baltic Sea Region Law Firm. In addition to rosé wine and sushi, we offer a highly topical, interesting conversation with experienced diplomats Ekéus and Mats Hellström on developments around the Baltic Sea.

To access the invitation, click here.

NB! Please notice that places are limited. To register, please send an e-mail to almedalen@magnussonlaw.com or Carl Michael Bergman at Opticom.

Download PDF

Opticom attended Läkemedelsdagen 2014 at Nalen where the road to a more equal health care for all was in focus.

Ordnat införande, horizon scanning and structured follow-up were topics that were presented and discussed. In the panel discussions where Anders Blanck, LIF, Hans Karlsson, SKL, Heidi Stensmyren, Läkarförbundet and Calle Waller, Prostatacancerförbundet participated, critiscism was expressed against the models’ focus to be more on order and structure and follow-up and very little on introduction.

There are different roads to take, either you can act in the existing systems, i.e. to do something that may not be good, but at least better than what is done today or you can do something new and make a difference. Representatives for the industry, patients and clinics consider “ordnat införande” to be a far too weak effort and point out there is a greater need for speed that cannot be accommodated in the current systems.

During the day more criticism was expressed towards the current health care system in Sweden:
“Today we have a very weak uptake of new drugs in Sweden and that is a major issue. Many believe we still have a growing budget for pharmaceuticas in Sweden, but this belief is wrong, this budget has not increased in many years.” (Robert Ström, LIF)

“There is a lot of money that is used wrongly in the health care system in Sweden. If we would use the money in the right way, we would not need any private health insurances. Just to move a recycle bin for batteries 2 meters can save hours for health care personnel and before we have looked at all these kinds of improvements, I think we should not start to discuss private health insurances.” (Barbro Westerholm (FP), member of parliament)

Download PDF